Physician profile
Eric B Levy
NPI 1750640322
$11,418.05
in general payments reported to CMS, 2019-2025
15 companies · $1,585 in 2025
The $1,585 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $130 · 2021: $209 · 2022: $4,430 · 2023: $363 · 2024: $4,485 · 2025: $1,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845 · Education: $2,508 · Travel and Lodging: $1,070 · Gift: $8.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.49 |
| Education | $2,508.16 |
| Travel and Lodging | $1,070.22 |
| Gift | $8.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,036.45 | 2022-2024 | Da Vinci Surgical System |
| Procept Biorobotics Corporation | $1,060.41 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Boston Scientific Corporation | $407.80 | 2019-2025 | General - Kidney Stone Disease |
| Janssen Biotech, INC. | $364.26 | 2020-2023 | Erleada |
| Calyxo, INC. | $357.82 | 2025 | Cvac Aspiration System |
| Urogen Pharma, INC. | $288.43 | 2022-2025 | |
| Astellas Pharma US INC | $233.93 | 2019-2025 | Padcev |
| Immunitybio, INC. | $189.67 | 2025 | |
| Pfizer INC. | $127.36 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $116.07 | 2024 | Keytruda |
| Astrazeneca Pharmaceuticals Lp | $103.00 | 2021 | |
| Laborie Medical Technologies Corp. | $45.42 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Sumitomo Pharma America, INC. | $42.98 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.00 | 2025 | |
| Glaxosmithkline, LLC. | $21.45 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Levy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.